MUC5AC and colitis: We found that HEAS improves DSS-induced experimental colitis by reduction of inflammatory and oxidative damage in colon, in a dose dependent-manner, mainly through the attenuation of inflammatory cytokines production and the improvement of intestinal mucin barrier.